PA
PTGX icon

Perceptive Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Perceptive Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130M Sell
1,230,879
-119,546
-9% -$10.6M 2.54% 10
2025
Q4 		$118M Buy
1,350,425
+320,291
+31% +$26.2M 2.1% 11
2025
Q3 		$68.4M Sell
1,030,134
-44,314
-4% -$2.52M 1.98% 17
2025
Q2 		$59.4M Sell
1,074,448
-16,823
-2% -$807K 2.2% 10
2025
Q1 		$52.8M Sell
1,091,271
-180,391
-14% -$7.56M 1.86% 12
2024
Q4 		$49.1M Sell
1,271,662
-102,901
-7% -$4.49M 1.35% 23
2024
Q3 		$61.9M Buy
1,374,563
+105,828
+8% +$4.28M 1.31% 27
2024
Q2 		$44M Buy
1,268,735
+274,412
+28% +$8.04M 1.06% 26
2024
Q1 		$28.8M Buy
994,323
+611,063
+159% +$16.6M 0.5% 56
2023
Q4 		$8.79M Sell
383,260
-671,013
-64% -$11.7M 0.2% 66
2023
Q3 		$17.6M Sell
1,054,273
-415,488
-28% -$8.06M 0.59% 47
2023
Q2 		$40.6M Buy
1,469,761
+504,609
+52% +$12.6M 1.18% 27
2023
Q1 		$22.2M Buy
+965,152
New +$16.2M 0.66% 42
2021
Q1 		– Sell
-203,591
Closed -$4.1M – 156
2020
Q4 		$4.1M Buy
+203,591
New +$4.38M 0.04% 124

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Perceptive Advisors's PTGX Position: Q1 2026 in Review

Perceptive Advisors reduced its Protagonist Therapeutics (PTGX) stake by 8.9% in Q1 2026, selling an estimated $10.6M and leaving 1,230,879 shares worth $130M. The position accounts for 2.54% of the portfolio, ranked #10.

Perceptive Advisors first reported a position in PTGX in Q4 2020 and has held it in 14 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Perceptive Advisors held 1,230,879 shares of Protagonist Therapeutics worth $130M as of Q1 2026.
  • Perceptive Advisors sold 119,546 Protagonist Therapeutics shares in Q1 2026, an estimated $10.6M.
  • Protagonist Therapeutics made up 2.54% of Perceptive Advisors's portfolio in Q1 2026, its #10 holding.
  • Perceptive Advisors first reported a position in Protagonist Therapeutics in Q4 2020 and has held it in 14 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Perceptive Advisors's 13F filing for Q1 2026, filed 15 May 2026.